Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints, although it can also impact other parts of the body. In RA, the immune system mistakenly attacks the synovium, the lining of the joints, leading to inflammation, swelling, and pain. Over time, this ongoing immune activity can result in cartilage breakdown, bone erosion, and permanent loss of joint function. In more advanced cases, RA may also contribute to broader health complications, including cardiovascular disease, osteoporosis, and metabolic disorders, significantly affecting overall quality of life.
Current treatments for RA, including nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs, are primarily designed to reduce inflammation and manage symptoms. While these therapies can be effective for many patients, they do not cure the disease and often carry the risk of long-term side effects. As a result, there is increasing interest in developing safer, more targeted approaches that address the underlying immune dysfunction driving RA rather than simply controlling its symptoms.
In this review, Lee et al. summarizes the immunomodulatory effects of MSCs in RA and their application in animal models and clinical trials.
The Role of the Immune System in RA
RA develops through a complex and sustained interaction between immune cells and inflammatory signals. The immune system produces autoantibodies, such as rheumatoid factor and anti-citrullinated protein antibodies, which mistakenly target the body’s own tissues. This triggers a cascade of inflammation that draws immune cells into the joints, where they release cytokines and other inflammatory molecules that further amplify the response.
At the same time, the joint environment becomes increasingly hostile. It is often characterized by low oxygen levels, high concentrations of reactive oxygen species, and a buildup of inflammatory mediators. This environment not only accelerates tissue damage but also interferes with the body’s natural repair processes. As inflammation persists, joint destruction progresses, leading to long-term functional impairment.
Why Mesenchymal Stem Cells Are a Promising Approach for Rheumatoid Arthritis
Mesenchymal stem cells (MSCs) have emerged as a promising area of research in the treatment of RA. These cells can be obtained from several sources, including bone marrow, adipose tissue, and umbilical cord tissue. What makes MSCs particularly compelling is their ability to both regulate immune responses and support tissue repair.
Unlike traditional therapies that primarily suppress inflammation, MSCs interact with the immune system in a more balanced and adaptive way. They can reduce harmful immune activity while simultaneously promoting regulatory pathways that help restore immune tolerance. This dual function positions MSCs as a strong candidate for treating autoimmune diseases like RA, where both immune imbalance and tissue damage play central roles.
How Mesenchymal Stem Cells Help Regulate the Immune System
A defining feature of MSCs is their ability to influence multiple immune cell types at once. They achieve this through a combination of signaling molecule release and direct cell-to-cell interactions, allowing them to coordinate a broader immune response rather than targeting a single pathway.
For example, MSCs can suppress the activity of T cells, which are key drivers of autoimmune inflammation in RA. At the same time, they promote the development of regulatory T cells, or Tregs, which help calm the immune system and prevent excessive inflammatory responses. This shift toward immune balance may play an important role in reducing ongoing joint damage.
In addition to their effects on T cells, MSCs also influence B cells, which are responsible for producing antibodies. By reducing B cell activity and limiting antibody production, MSCs may decrease the formation of harmful autoantibodies associated with RA.
MSCs further interact with macrophages, another critical component of the immune system. They encourage these cells to shift from a pro-inflammatory state to one that supports tissue repair and healing. This transition helps reduce inflammation within the joints while promoting a more regenerative environment.
Improving the Inflammatory Microenvironment
RA is not only a disease of immune dysfunction but also one of a disrupted and damaging tissue environment. Within affected joints, inflammatory signals, oxidative stress, and poor oxygen supply combine to sustain ongoing damage and limit healing.
MSCs help address this challenge by releasing a wide range of bioactive molecules that can reshape the local environment. These include factors such as prostaglandin E2 and nitric oxide, which work to reduce inflammation and oxidative stress. By modifying the surrounding conditions, MSCs create an environment that is more supportive of tissue repair and less conducive to chronic inflammation.
This ability to influence both immune activity and the tissue microenvironment is a key reason MSCs are considered a regenerative therapy rather than simply an anti-inflammatory treatment.
Evidence From Preclinical Research
Much of the current understanding of MSC therapy in RA comes from preclinical studies, particularly animal models that closely resemble the disease. In these studies, MSC treatment has consistently been associated with reduced joint inflammation, lower levels of inflammatory cytokines, and improved joint function.
For instance, MSCs have been shown to decrease levels of key inflammatory molecules such as interferon gamma and interleukin-17, both of which are strongly linked to disease progression. These reductions are often accompanied by decreased swelling and less structural joint damage.
Researchers have also explored combining MSC therapy with existing treatments to enhance therapeutic effects and potentially reduce side effects. While early findings are promising, further research is needed to determine how these combined approaches can be optimized.
Clinical Research and Early Human Studies
Early clinical studies investigating MSC therapy in RA have produced encouraging results, particularly in terms of safety. Most patients receiving MSC treatment have tolerated the therapy well, with few reports of serious adverse effects.
In addition to safety, some studies have observed reductions in inflammatory markers along with improvements in symptoms such as joint pain and swelling. These findings suggest that MSCs may help modulate disease activity in real-world patient populations, not just in controlled laboratory settings.
However, clinical outcomes have not been entirely consistent. Differences in cell source, dosing strategies, and delivery methods can all influence results, highlighting the need for larger and more standardized studies to identify the most effective treatment protocols.
Challenges and Limitations
Despite their strong potential, MSC therapies face several important challenges. One of the primary obstacles is the harsh environment within RA-affected joints. Conditions such as low oxygen levels, high inflammation, and oxidative stress can reduce the survival and effectiveness of transplanted cells.
To overcome this, researchers are exploring strategies to enhance MSC performance before transplantation. These approaches, often referred to as preconditioning, may involve exposing the cells to specific signals or modifying them to improve their resilience and therapeutic activity.
Another challenge is variability. MSCs derived from different tissue sources may behave differently, and there is currently no standardized approach to how they are prepared or administered. This lack of consistency makes it difficult to compare study results and establish best practices.
The Future of MSC Therapy in Rheumatoid Arthritis
MSCs represent a meaningful shift in how RA may be treated in the future. Rather than simply suppressing immune activity, these therapies aim to restore balance, reduce inflammation, and support the body’s natural repair processes.
Ongoing research is focused on improving the effectiveness of MSC therapy by optimizing cell sources, refining delivery methods, and gaining a deeper understanding of how these cells interact with the immune system. There is also growing interest in MSC-derived extracellular vesicles, which may offer similar therapeutic benefits without requiring live cell transplantation.
Although MSC therapy is not yet a standard treatment for RA, it continues to show strong potential as a safer and more comprehensive approach. As the field of regenerative medicine advances, MSC-based therapies may play an increasingly important role in improving outcomes and quality of life for individuals living with rheumatoid arthritis.
Source: Lee KS, Yeom SH, Kim MK, Woo CH, Choi YC, Choi JS, Cho YW. Therapeutic potential of human stem cell-derived extracellular vesicles in idiopathic pulmonary fibrosis. Extracell Vesicles. 2024;4:100045. doi: 10.1016/j.vesic.2024.100045.